Beam Therapeutics
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Beam Therapeutics
Beam Therapeutics Inc. 是一家生物技術公司，在美國為患有嚴重疾病的患者開發精準基因藥物。公司正在開髮用於治療鐮狀細胞病和β地中海貧血的BEAM-101； BEAM-102 用於治療鐮狀細胞病；和 BEAM-201，一種用於治療復發/難治性 T 細胞急性淋巴細胞白血病的同種異體嵌合抗原受體 T 細胞；和 BEAM-301，一種用於治療 Ia 型糖原貯積病患者的肝臟靶向開發候選藥物。它還開發了 alpha-1 抗胰蛋白酶缺乏症的療法；眼部疾病；和其他肝臟、肌肉和中樞神經系統疾病。公司與波士頓兒童醫院結盟；與 Magenta Therapeutics, Inc. 的研究和臨床試驗合作協議；與 Sana Biotechnology, Inc. 的許可協議；以及與巴塞爾分子與臨床眼科研究所的研究合作。它還與輝瑞公司和 Apellis Pharmaceuticals, Inc. 簽訂了研究合作協議；與 Verve Therapeutics , Inc .的合作和許可協議。該公司成立於2017年，總部位於馬薩諸塞州劍橋。
如何購買 Beam Therapeutics (BEAM)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 BEAM
透過 RockFlow App 或網頁端搜尋 BEAM，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.